# Development of small molecule therapeutics for mitigating opioid withdrawal syndrome

> **NIH NIH R44** · EVODENOVO, INC. · 2024 · $880,957

## Abstract

Project Summary
 The use of opioids for managing pain is widespread, but it is plagued by several limitations, including the
development of dependence, decreasing efficacy over time, and adverse somatic effects. Opioid use disorder
(OUD) is a growing global health problem with a market size of $4.81 billion by 2028. The current standard of
care involves using opioid replacement therapies such as methadone and buprenorphine, however, these
treatments are associated with high rates of relapse and problematic side effects.
 All opioid drugs target the μ-opioid receptor (MOR) to produce both positive therapeutic results and
negative side effects. Research conducted on the MOR has demonstrated the possibility of segregating its
downstream signaling pathways to preserve pain relief while reducing the risks of dependence. However,
achieving that goal solely by targeting MOR is challenging. EvoDenovo founders uncovered a G protein-coupled
receptor GPR139 with “anti-opioid” activity, which selectively separates the behavioral effects of opioids. This
discovery has the potential to enhance opioid pain relief while reducing dependence, making it a promising
treatment for OUD. The project aims to develop small molecule compounds to treat OUD by targeting GPR139.
Evodenovo assembled a multi-disciplinary team of wide ranging expertise in genetic neuronal models, GPCR
signaling, medicinal chemistry and opioid pharmacology to pursue the following Aims: 1) Develop drug-like small
molecule inhibitors of GPR139, 2) Optimize lead compounds for modulation of opioid effects in endogenous
neuronal systems, and 3) Perform testing of GPR139 lead compounds for opioid effects in rodents. The overall
goal of this project is to identify the most promising compounds that can effectively reduce opioid dependence
in mouse models. The following steps will involve obtaining IND designation, manufacturing, conducting clinical
trials, and ultimately gaining approval from the FDA. This will enable the commercialization of a pioneering
therapeutic solution for the treatment of opioid use disorder (OUD).
EvoDenovo RFA-DA-23-021/ PI: Sid A. Labed Project Summary - Page 1 of 1

## Key facts

- **NIH application ID:** 10785942
- **Project number:** 2R44DA053844-02
- **Recipient organization:** EVODENOVO, INC.
- **Principal Investigator:** Sid Ahmed Labed
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $880,957
- **Award type:** 2
- **Project period:** 2022-04-15 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10785942

## Citation

> US National Institutes of Health, RePORTER application 10785942, Development of small molecule therapeutics for mitigating opioid withdrawal syndrome (2R44DA053844-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10785942. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*